{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-051640","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.492588+00:00","generated_at":"2026-06-03T07:30:54.923267+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Standard BioTools cuts 10% of workforce, targets $45-50M annual savings in FY2025","bullets":["Reduction-in-force of ~10% including senior management positions eliminated after SomaLogic merger.","Expected annualized operating expense savings of $45-$50 million in fiscal 2025, majority in H2 2024.","Restructuring costs of $10-$11 million, including $4 million non-cash share-based vesting expenses.","Closure of San Diego R&D facility; prioritization of R&D spend to improve operational efficiency.","Q1 2024 earnings call scheduled for May 8, 2024 at 1:30 p.m. PDT."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-051640","json":"https://secwatch.observer/filing/0001104659-24-051640.json","markdown":"https://secwatch.observer/filing/0001104659-24-051640.md","text":"https://secwatch.observer/filing/0001104659-24-051640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/0001104659-24-051640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/tm249061d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:30:54.923267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0317ad8c282ca2335655bcfb8ea77da02660a01c","claim":"STANDARD BIOTOOLS INC. announced a restructuring with charges of Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million affecting total workforce (approximately 10% of its total workforce).","evidence_excerpt":"On April 25, 2024, Standard BioTools Inc. (the “Company”) announced a reduction-in-force of approximately 10% of its total workforce, including the elimination of certain senior management positions following the closing of the Company’s merger with SomaLogic, Inc., as part of an operational restructuring plan.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/0001104659-24-051640-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million"},{"label":"Affected area","value":"total workforce"},{"label":"Headcount","value":"approximately 10% of its total workforce"}],"fact_type":"restructuring_charge"},{"claim_id":"22b8ecd6abbd49a0c124984217c2e5069f1b5989","claim":"STANDARD BIOTOOLS INC. announced a restructuring with charges of Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr affecting R&D facility in San Diego and overall SG&A expenses.","evidence_excerpt":"Streamlined Operational Expenditures: Includes reductions in overall selling, general and administrative (SG&A) expenses, the closure of the Company’s R&D facility in San Diego, as well as savings related to a more prioritized R&D strategy.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924051640/0001104659-24-051640-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr"},{"label":"Affected area","value":"R&D facility in San Diego and overall SG&A expenses"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}